Pliant Therapeutics, Inc. — Form 8-K Summary
Business context and reporting period
Pliant Therapeutics, Inc. filed a Form 8-K dated May 9, 2022, under Item 2.02 to announce financial results for the first quarter ended March 31, 2022. The filing covers the company’s Nasdaq-listed common stock under the ticker PLRX.
Financial results and liquidity
The filing states that a press release containing the first-quarter 2022 financial results was issued and furnished as Exhibit 99.1. The provided filing text does not include the press release or clear values for revenue, net income or loss, cash flow, margins, debt, cash, cash equivalents, investments, or liquidity.
Material changes versus the prior comparable period
The provided text does not disclose financial comparisons or material changes versus the first quarter of 2021.
Guidance, outlook, risks, and unusual items
No guidance, updated outlook, management commentary, risk discussion, contingencies, or unusual items are included in the provided Form 8-K text. The filing states that the information furnished under Item 2.02 and the related exhibit is not deemed filed for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings.
Key facts for investors to verify
- Review Exhibit 99.1 for the complete first-quarter 2022 financial results and management commentary.
- Verify reported cash, investments, operating cash burn, and expected liquidity runway.
- Verify revenue, operating expenses, net loss, loss per share, and comparisons with the prior-year period.
- Check for any updated clinical, regulatory, financing, collaboration, or pipeline developments in the press release.